Cubosomal Lipid Formulation for Combination Cancer Treatment: Delivery of a Chemotherapeutic Agent and Complexed α-Particle Emitter $^{213}$Bi

Adrianna Cytryniak, Kinga Żelechowska-Matysiak, Ewa Nazaruk, Renata Bilewicz, Rafał Walczak, Emilia Majka, Adam Mames, Frank Bruchertseifer, Alfred Morgenstern, Aleksander Bilewicz, and Agnieszka Majkowska-Pilip*

Cite This: Mol. Pharmaceutics 2022, 19, 2818−2831

ACCESS Metrics & More | Article Recommendations | Supporting Information

ABSTRACT: Here, we propose tailored lipid liquid-crystalline carriers (cubosomes), which incorporate an anticancer drug (doxorubicin) and complexed short-lived α-emitter (bismuth-213), as a strategy to obtain more effective action toward the cancer cells. Cubosomes were formulated with doxorubicin (DOX) and an amphiphilic ligand (DOTAGA-OA), which forms stable complexes with $^{213}$Bi radionuclide. The behavior of DOX incorporated into the carrier together with the chelating agent was investigated, and the drug liberation profile was determined. The experiments revealed that the presence of the DOTAGA-OA ligand affects the activity of DOX when they are incorporated into the same carrier. This unexpected influence was explained based on the results of release studies, which proved the contribution of electrostatics in molecular interactions between the positively charged DOX and negatively charged DOTAGA-OA in acidic and neutral solutions. A significant decrease in the viability of HeLa cancer cells was achieved using sequential cell exposure: first to the radiolabeled cubosomes containing $^{213}$Bi complex and next to DOX-doped cubosomes. Therefore, the sequential procedure for the delivery of both drugs encapsulated in cubosomes is suggested for further biological and in vivo studies.

KEYWORDS: cubosomes, α-therapy, $^{213}$Bi radionuclide, doxorubicin, cytotoxicity, cancer cells

1. INTRODUCTION

Surgery, chemotherapy, and external radiotherapy are the most common therapies currently used for cancer treatment. However, for addressing the spread of cancers, chemotherapy is the most commonly used therapy. One of the most widespread chemotherapeutic drugs for the treatment of solid tumors and malignancies, malignant lymphoma, and acute leukemia is doxorubicin (DOX). However, like other chemotherapeutic agents, there are serious limiting factors for the clinical applications of DOX, such as dose-dependent irreversible cardiotoxicity and poor specificity.1,2 These factors lead to the administration of suboptimal doses of DOX. As a result, therapeutic failure and development of drug resistance are observed.

Another important strategy in cancer treatment is internal radiation therapy—endoradiotherapy,3 which represents an alternative therapeutic method and has advantageous features compared to chemotherapy and external radiation therapies. Intelligent dose delivery concepts using small molecules, peptides, or antibodies as radionuclide carriers enable the selective accumulation of the radiation sources in the tumor lesion and reduction of radiation toxicity for the peripheral organs. Bioconjugates labeled with β−- or α-emitting radionuclides have found widespread use in cancer therapy.4–9 $^{90}$Y- and $^{177}$Lu-labeled peptides or small molecules, like PSMA-617, somatostatin, and bombesin analogues, show very promising results.5,6 DOTATATE, a drug labeled with $^{177}$Lu (Lutathera), was approved by the U.S. Food and Drug Administration (FDA) in 2018 for the treatment of certain neuroendocrine tumors. A challenge associated with β−-emitting targeted radionuclide therapies is the inherent toxicity caused by the death of normal healthy cells, resulting from crossfire radiation damage from the relatively long ranges of the β− particles in the tissue.7 An emerging strategy is the use of targeted α-particle therapy.8–10 The use of α-particles in the targeted
radionuclide therapy offers a beneficial alternative to the use of β-particles. α-particles deposit all of their energy within a much shorter range, equating to a few cell diameters (50–100 μm). As a result, targeted α-radiotherapy agents have great potential for the treatment of small and disseminated tumors. It also has possible therapeutic applications in the treatment of microparticles. 177Lu-PSMA-

possible therapeutic applications in the treatment of microparticles. 177Lu-PSMA-

α-particle therapy offers a beneficial alternative to the use of short-lived α-particle emitters. As a result, targeted α-radiotherapy agents have great potential for the treatment of small and disseminated tumors. It also has possible therapeutic applications in the treatment of microparticles. 177Lu-PSMA-

radionuclide therapy are the following: 213Bi, 212Bi, 212at, 212Pb, 212Th, 225Ac, and 221Ac. 13 Of all the α-emitters used now for targeted radionuclide therapy, 212Bi proved to be a promising radionuclide for cancer treatment in clinical investigations. 212Bi is a decay product of 225Ac and decays further to stable 211Bi through two branches each involving one α decay and two β− decays. 9,15 212Bi can be easily distributed in the form of an 225Ac/211Bi generator and can be conveniently obtained immediately before application. 212Bi-labeled radioligands are used for the treatment of glioma,16,17 neuroendocrine tumors,18 leukemia,19,20 melanoma,21–23 and bladder cancer. 24

A better understanding of tumor biology has led to the development of lipid drug delivery nanosystems with multiple functionalities. 25 Liposomes have been reported as useful carriers of α emitters. 26–31 The lipid nanoparticles, e.g., liposomes, cubosomes, and hexosomes, allow multimodal therapy, such as chemotherapy in combination with endoradiotherapy. Larsen et al. 32 used the commercial drug, doxorubicin, encapsulated in pegylated liposomes (Caelyx/Doxil), to perform the synthesis of 223Ra-containing radiobiocjugates inside the carriers. Liposome-encapsulated 223Ra displayed beneficial physical and radiological characteristics including in vivo stability and promising biodistribution properties in mice. Lipidic liquid-crystalline phases and nanoparticles used in the present work are promising drug carriers since compared to liposomes, they have a much larger interfacial area (400 m2/g) and can efficiently bind larger amounts of hydrophilic and hydrophobic drugs. 33,34 The lipid cubic phase can be characterized as a curved, nonintersecting lipid bilayer with two unconnected water channels. 35 Monoolein (GMO) is the lipid most commonly used to prepare the cubic phase as it is biodegradable, biocompatible, and nontoxic. 36 Because of high viscosity, the cubic phase may be difficult to handle; therefore, such a mesophase in the presence of a stabilizer can be dispersed into cubosomes, which are kinetically stable colloidal nanoparticles. 37–39 Cubosomes retain the internal bicontinuous structure and all of the physicochemical features of the cubic phase that control the drug release kinetics. 40–42 The versatility of lipid liquid-crystalline systems in encapsulating and delivering therapeutic agents of different solubilities, charges, and sizes has been proven to overcome problems occurring with other drug carriers, such as small encapsulation efficiency, toxicity, or poor stability. 43–45 Cubosomes have been explored for anticancer drug delivery 46–48 and combined delivery of different active agents. 49–51 We recently reported the enhancement of cytotoxicity achieved when doxorubicin is used together with a complex of 177Lu (t1/2 = 6.7 days) but only after a shorter incubation of HeLa cells.

In the present study, we investigate the liquid-crystalline systems as a platform for combined chemotherapy with α-particle therapy using doxorubicin as a chemotherapeutic agent and a short-lived α-particle emitter 212Bi (t1/2 = 45.6 min).

A chelating ligand, DOTAGA-oleylamine (DOTAGA-OA), was incorporated into cubosomes to form a stable complex with 211Bi. The hydrophobic oleylamine tail anchors the ligand in the lipid bilayer of the cubosome structure, while the DOTAGA headgroup with the radioactive dopant is exposed to the water channels. Small-angle X-ray scattering (SAXS) was employed to perform the structural characterization of cubosome formulations, and cryogenic transmission electron microscopy (cryo-TEM) was used for cubosome imaging. The characteristics of the carriers were supplemented with dynamic light scattering (DLS) measurements of their sizes and stabilities. The biological experiments revealed that the presence of the DOTAGA-OA ligand affects the activity of DOX when they are incorporated in the same carrier. This unexpected influence was explained based on the results of release studies showing the pH-dependent molecular interaction between the two moieties. Taking these interactions into account allowed for the elaboration of the optimal way for the drugs, doxorubicin and complexed 212Bi delivery, to achieve the increased cytotoxic effect and obtain more effective action toward the malignant cells.

2. EXPERIMENTAL SECTION

2.1. Reagents. Monoolein (1-oleoyl-rac-glycerol, GMO) of purity ≥ 99%, doxorubicin hydrochloride (DOX), and Pluronic F-127 used for cubosome preparation were all obtained from Sigma-Aldrich (St. Louis, MO). To prepare MES buffer, 0.1 M 2-(N-morpholino)ethanesulfonic acid or 0.1 M 2-amino-2-(hydroxymethyl)-1,3-propanediol was titrated with 0.1 M NaOH or 0.1 M HCl (Polish Chemicals Co., Gliwice, Poland) to obtain the required pH of the buffer. Milli-Q water (18.2 MΩ cm−1; Millipore, Bedford, MA) was used to prepare all solutions.

DOTAGA-OA ligand was synthesized according to a previously described procedure. 35 Analysis glass microfiber sheets (Agilent, Santa Clara, CA) were used for instant thin-layer chromatography (ITLC).

Cell experiments were performed with the use of the following materials: RPMI-1640 medium, fetal bovine serum, phosphate-buffered saline (PBS), trypsin–EDTA, and penicillin/streptomycin solutions from Biological Industries (Biological Industries, Beth Haemek, Israel); dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO); CellTiter-96 aqueous one solution reagent (MTS compound) from promega (Promega, Madison, WI); FITC Annexin V and propidium iodine (PI) staining solution from BD Biosciences (BD Biosciences, San Jose, CA); and Hoechst 33342 from Thermo Fisher Scientific, Inchinnan, Scotland.

A human-derived HeLa cancer cell line was obtained from the American Type Culture Collection (ATCC, Rockville, MD) and was cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. The cells were grown at 37 °C in a humidified atmosphere containing 5% CO2.

2.2. Radionuclides. 212Bi was obtained from the radio-nuclide generator loaded with its longer-lived mother nuclide 225Ac. 225Ac/212Bi standard generator with 0.3 mL of AG MP-
S0 resin in perfluoroalkoxy tubing with polypropylene fittings equipped with silicone tubing was used (Joint Research Centre, European Commission, Karlsruhe, Germany). The resin was preconditioned using 6 M HCl, 0.05 M HNO$_3$, 6 M HNO$_3$, and finally, 0.05 M HNO$_3$. Directly before loading $^{225}$Ac, the resin was washed with 2 mL of 4 M HNO$_3$. A 600 µL solution of 0.1 M HCl/0.1 M NaI was used as an eluent. The strong affinity of Bi(III) for complexation with iodide was used for the selective elution of $^{213}$Bi from the cation-exchange resin as anionic Bi$_4$I$_7$/Bi$_2$I$_2$ species. Breakthrough of $^{225}$Ac after this procedure was lower than 5%. The generator was ready for elution 3 h after loading, with an efficiency of 93.8%.

2.3. Preparation of Cubic Phases and Cubosomes. To prepare the bulk nondoped cubic phase, an appropriate amount of molten monoolein (GMO) and MES buffer solution was mixed together. The ratio of components was chosen on the basis of the phase diagrams for the GMO/water system. Cubic phases with incorporated DOX were prepared similarly as described above, but first, DOX was dissolved in the buffer solution and then mixed with the appropriate amount of molten GMO. DOTAGA-OA was dissolved first in a chloroform/methanol mixture (4:1 v/v) and then used for the preparation of mesophases. Next, solvent evaporation was performed and DOTAGA-OA was mixed with molten GMO. Then, MES buffer solution was added. The final compositions of cubic phases with DOTAGA-OA are presented in the Supporting Information, Table S1. To prepare mesophases loaded with DOX and DOTAGA-OA together, a chloroform/methanol mixture (4:1 v/v) was used as a solvent to dissolve DOTAGA-OA. Solvent evaporation was performed, and DOTAGA-OA was then mixed with molten GMO. Next, DOX in MES buffer solution was added. Samples were stabilized for at least 24 h to obtain transparent, viscous, and homogeneous cubic phases. The obtained samples were stored in sealed vials at room temperature and protected from light.

Cubosomes were synthesized according to a previously described protocol. A top-down approach was employed. Briefly, cubosome preparation involved the hydration of GMO with MES buffer solution and Pluronic F-127 stabilizer. Next, the samples were sonicated in a Sonic 0.5 ultrasonic bath (Polsonic, Poland). On the basis of radiolabeling conditions, the amount of DOTAGA-OA in the cubosomal formulations was selected.

In Table 1, the final composition of the cubic phases and cubosomes is presented.

| cubic phase | final compositions of samples | ratio of the components (wt %) |
|-------------|-----------------------------|-----------------------------|
| blank       | buffer/GMO                  | 40/60                       |
| DOX         | buffer/GMO/DOX              | 39.8/60/0.2                 |
| DOX DOTAGA-OA | buffer/GMO/DOTAGA-OA     | 39.8/58.1/0.2/1.9           |
| cubosomes   |                             |                             |
| blank       | buffer/GMO/F-127            | 94.62/4.84/0.54             |
| DOX         | buffer/GMO/DOX/F-127        | 94.58/4.86/0.02/0.54        |
| DOTAGA-OA   | buffer/GMO/DOTAGA-OA/F-127 | 94.45/4.85/0.16/0.54        |
| DOX DOTAGA-OA | buffer/GMO/DOTAGA-OA/F-127 | 94.44/4.84/0.02/0.16/0.54   |

2.4. Characterization Methods of Mesophases. 2.4.1. Small-Angle X-ray Scattering (SAXS). SAXS was employed to determine the structure of cubic phases and cubosomes. SAXS measurements were carried out on a Bruker Nanostar system equipped with a Vantec 2000 area detector (Madison, WI) and Cu Kα radiation. X-ray measurements allowed us to determine the properties of liquid crystals such as the crystal lattice parameter and water channel diameter (Supporting Information, 15).

2.4.2. Dynamic Light Scattering (DLS). DLS (Zetasizer Nano ZS Malvern, U.K.) was used to determine the average size, polydispersity (PDI), and zeta potential (ζ) of cubosomes. The measurements were performed at 25 °C, and the viscosity of pure water was assumed. Results are presented as an average of three separate measurements.

2.4.3. Cryogenic Transmission Electron Microscopy (cryo-TEM). Three microliters of cubosome dispersions were applied onto glow-discharged Quantifoil R2/2 holey carbon grids and plunge-frozen in liquid ethane using a Vitrobot Mark IV device (Thermo Fisher Scientific, Waltham, MA). Two-dimensional electron cryomicroscopy images were taken in the linear mode on a Thermo Fisher Glacios TEM (Waltham, MA) microscope operating at 200 kV, equipped with a 4k × 4k Falcon 3EC direct electron detection camera and EPU 2.10 software. The following parameters were used for collecting images: magnification of 92k corresponding to a pixel size of 0.15 nm (1.5 Å) at the specimen level; defocus set to 4.0 and 3.5 μm; and the total electron dose of approximately 40 e/Å².

2.4.4. Electrochemistry. Electrochemical experiments were performed with a CHI 700B bipotentiostat (CH Instruments Inc., Austin, TX) that has a standard three-electrode arrangement in buffered solution. Ag/AgCl was used as the reference electrode and a platinum foil was used as the counter electrode. The working electrode was a glassy carbon electrode (GCE, A = 0.07 cm²) modified with the cubic phase. Before the experiments, the working electrode was polished on the alumina of decreasing size (from 0.3 to 0.05 μm) with a polishing cloth. The electrodes were subsequently sonicated to remove adhered alumina particles, rinsed with ethanol and water, and left to dry. Cyclic voltammetry (CV) and differential pulse voltammetry (DPV) were used to determine the doxorubicin release from the mesophase. The mesophase was deposited on the electrode surface by means of a Teflon cap, which kept the thickness of the mesophase layer equal to 0.5 mm and the volume of the layer remained constant in all experiments.

After covering the electrode with the cubic phase layer, it was immediately immersed in the deoxygenated buffer solution. All experiments were carried out at room temperature in solutions deoxygenated by purging with argon (99.999%) for 15 min, and then an argon blanket was kept over the solution surface. For each type of measurement, triplicate experiments were performed.

2.4.5. Release Studies. To obtain the release profile from cubosomes, nanoparticles with DOX or DOX and DOTAGA-OA together were placed in the dialysis membrane (MWCO 12–14 kDa) and submerged in 50 mL of MES buffer, pH 5.5. To determine the release rate of DOX from nanoparticles, UV–vis spectroscopy was applied using a UV–vis Cary 60 spectrophotometer (Agilent Technologies, Warsaw, Poland). At least 10 dilutions in the concentration range of 0.0005–0.1 mg/mL were used to obtain the standard calibration curve for DOX solution in 0.1 M MES buffer at pH 5.5. The wavelength range of 600–250 nm with the characteristic λ at 480 nm was
selected to measure the absorption spectra of the DOX buffer solutions. All of the measurements were performed at room temperature (25 °C).

### 2.5. Protocol for Cubosome Radiolabeling

Six hundred microliters of 0.1 M HCl/0.1 M NaI elution from $^{213}$Bi generator (20 MBq) was added to 6 µL of cubosomes doped with DOTAGA-OA (10 nmol in 6 µL of cubosome dispersion). Samples were placed in Eppendorf tubes, and 400 µL of tris buffer (0.1 M, pH 7.0) was added. The solution was heated at 95 °C for 20 min and cooled to room temperature. The instant thin-layer chromatography (ITLC) method with citrate buffer (0.5 M, pH 5.5) as the mobile phase and glass microfiber TLC plates was used to determine the labeling efficiency. In this method, the unbound $^{213}$Bi moves with the front of the solvent ($R_f = 1$) and labeled conjugates remain at the baseline ($R_f = 0$). The radioactivity distribution on the ITLC strips was measured by a Cyclone Plus Phosphor Imager (Perkin–Elmer life and analytical sciences, Shelton, CT) and analyzed using Optiquant software supplied by the manufacturer.

#### 2.6. In Vitro Cytotoxicity Assay: MTS

To determine the cell metabolic activity, the MTS test was used. Cytotoxicity studies were carried out for cubosome dispersions containing $^{213}$Bi-DOTAGA-OA and $^{213}$Bi-DOTAGA-OA with DOX. Blank cubosomes (GMO concentration: 55 µg/mL) and cubosomes doped with DOX (DOX concentration: 0.2 µg/mL) were used as controls.

HeLa cells were plated in 96-well plates at a density of 2 x 10^4 cells per well at 37 °C in a humidified environment of 5% CO₂ for 24 h. Then, cells were washed with PBS and increasing doses of $^{213}$Bi (500, 1000, and 2000 kBq/mL) in cubosomes suspended in the cell culture medium solution were added at a volume of 100 µL per well. After 24 h, the solution was removed, and cells were washed with PBS and treated with blank cubosomes or cubosomes doped with DOX suspended in cell culture medium. Further, the treated cells were incubated for the next 48, 72, and 96 h. The MTS assays were performed using the CellTiter-96 AQueous-Non-Radioactive Cell Proliferation Assay (Promega, Mannheim, Germany). The absorbance of the formazan product was measured at 490 nm using a microplate reader (Perkin-Elmer Life and Analytical Sciences, San Jose, CA).

#### 2.7. Flow Cytometry Assays

Two flow cytometry tests were performed—the apoptosis and cell cycle assays. For this purpose, HeLa cells cultured in RPMI-1640 medium with 10% FBS and 1% penicillin–streptomycin supplementation were used. HeLa cells were seeded (4 x 10^3 per well) in six-well plates and incubated for 24 h at 37 °C in the 5% CO₂ atmosphere. Next, the compounds presented in Table 2 were added to the wells and incubated for 24 and 48 h. Cells for apoptosis testing were trypsinized, washed twice with cold phosphate buffer (PBS), and resuspended in Annexin V binding buffer. Then, 5 μL of FITC-labeled Annexin V and 5 μL of propidium iodide (PI) were added followed by incubation for 15 min at 37 °C in the dark.

Samples for the cell cycle analysis were prepared identically as samples for apoptosis assay. After washing twice with cold PBS, cells were suspended in 70% cold EtOH and then frozen for 90 min. After centrifugation, the cells were washed twice with PBS, and 20 µL of propidium iodide (PI) and 2 µL of RNase were added. Apoptosis and cell cycle assays were performed with the use of flow cytometry FACS Celesta (BD Biosciences, San Jose, CA), while the analysis of the results was carried out using FACSDiva software v8.0 (BD Biosciences, San Jose, CA).

#### 2.8. Spheroids

Spheroid formation was initiated by seeding HeLa cells into a 96-well plate with the ultralow attachment surface (Corning, NY). They were grown to the size of 375 μm. Next, three-dimensional (3D) aggregates of cells were treated with 500 and 2000 kBq/mL of $^{213}$Bi in cubosome solutions. Spheroids were incubated with the radiocompounds for 24 h, and then the solution was removed. Spheroids were treated with blank cubosomes or cubosomes doped with DOX suspended in cell culture medium. After 24 h incubation, spheroids were suspended in fresh medium, which was then replaced every 2 days. Additionally, spheroids treated with an activity concentration of 0.5 MBq/mL were also stained with fluorescent reagents such as propidium iodide and Hoechst 33258. The growth of individual 3D cell culture models was measured for up to 12 days after treatment. To determine the diameter of spheroids, a Primovert microscope with an AxioCam 305 color (Zeiss, Jena, Germany) was applied. Measurements were performed with ZEN 3.0 lite software (Zeiss, Jena, Germany).

#### 2.9. Statistical Analysis

GraphPad Prism version 8.0 software (GraphPad Software Inc., San Diego, CA) was used to analyze the experimental data. To determine the cytotoxicity (MTS assay, flow cytometry analysis), values between groups were compared using one-way ANOVA. The results are presented as the mean ± standard error of the mean (SEM) and were considered statistically significant when $p ≤ 0.05$, $p ≤ 0.01$, $p ≤ 0.001$, and $p ≤ 0.0001$.

### 3. RESULTS AND DISCUSSION

#### 3.1. Characterization of Cubic Phases and Cubosomes

##### 3.1.1. Small-Angle X-ray Scattering (SAXS)

SAXS was employed to characterize the structure of the various lipidic liquid-crystalline phases. Figure 1A shows the SAXS diffraction patterns obtained for mesophases doped with different amounts of DOTAGA-OA, DOX or DOX, and DOTAGA-OA together.

For the blank cubic phase, the diffraction patterns showed reflections in the ratios of $2\sqrt{3}$, $\sqrt{3} \cdot \sqrt{4}$, $\sqrt{4}$, $\sqrt{6}$, $\sqrt{8}$, and $\sqrt{9}$, which corresponds to the double diamond cubic (Pn3m) symmetry and a lattice parameter of 10.0 nm. Structural parameters are presented in Table 3. The progressive incorporation of DOTAGA-OA up to 15 wt % did not affect the symmetry of the phase but instead resulted in an increased

| Table 2: Procedures of Dosing of Samples and Cell Culture Media |
|---------------------------------|-----------------|-----------------|
| short name of sample delivered sequentially or together | 1st dose (24 h) | 2nd dose (48 h) |
| control | cell culture medium | cell culture medium |
| $^{213}$Bi-Cub/Cubo | $^{213}$Bi-DOTAGA-OA in cubosomes | blank cubosomes |
| Cubo/DOX-Cubo | blank cubosomes | cubosomes doped with 0.2 μg/mL DOX |
| $^{213}$Bi-Cubo/DOX-Cubo | $^{213}$Bi-DOTAGA-OA in cubosomes | cubosomes doped with 0.2 μg/mL DOX |
| ($^{213}$Bi-Cubo + DOX)-Cubo | drugs added together in one cubosome | |

https://doi.org/10.1021/acs.molpharmaceut.2c00182
Mol. Pharmaceutics 2022, 19, 2818–2831
unit cell parameter (17.5 nm) and water channel dimensions of up to 10.1 nm (Figure 1B). This occurs as a result of
electrostatic repulsions of the negatively charged DOTAGA headgroup exposed to the water channel of the cubic phase. Mesophase with an addition of both DOX (0.2 wt %) and DOTAGA-OA (1.9 wt %) exhibited a minor increase of the lattice parameter (10.1 nm). Therefore, the dopants did not affect the symmetry of the phase.

SAXS was also used to elucidate the type and structural parameters of the cubosomes doped with DOX, DOTAGA-OA, DOX, and DOTAGA-OA together. Figure 2 presents one-dimensional diffraction patterns for obtained systems showing reflections in the ratio of $\sqrt{2}$, $\sqrt{4}$, and $\sqrt{6}$, which corresponds to the $\text{Im}3\text{m}$ (primitive) structure.\textsuperscript{58,59}

The addition of a small amount of DOX (0.02 wt %) did not significantly alter the properties of the cubosomes (Table 4). Incorporation of DOTAGA-OA (0.16 wt %) into cubosomes resulted in an increase in the crystallographic unit cell parameter, but the primitive cubic structure was preserved. Furthermore, the introduction of the DOX and DOTAGA-OA
together did not alter the internal structure of the cubosomes. The lattice parameter is decreased for all samples at 37 °C.

### 3.1.2. Physicochemical Characterization of Cubosomes.

Dynamic light scattering (DLS) was employed to provide information on the physicochemical properties of cubosomal formulations. The hydrodynamic diameter, polydispersity index (PDI), and zeta potential are presented in **Table 4**.

| cubosome formulation | unit cell (nm) | diameter of the aqueous channel (nm) | hydrodynamic diameter (nm) | PDI | ζ potential (mV) |
|----------------------|----------------|--------------------------------------|---------------------------|-----|-----------------|
| blank                | 14.0ᵃ         | 5.0ᵃ                                 | 140 ± 5                   | 0.18 ± 0.02 | −29 ± 0.9       |
| 12.9ᵇ                 |                |                                      |                           |      |                 |
| DOX                  | 13.7ᵃ         | 4.8ᵃ                                 | 160 ± 10                  | 0.19 ± 0.01 | −24 ± 0.4       |
| 12.7ᵇ                 |                |                                      |                           |      |                 |
| DOTAGA-OA            | 14.7ᵃ         | 5.4ᵃ                                 | 130 ± 15                  | 0.12 ± 0.02 | −20 ± 0.6       |
| 14.0ᵇ                 |                |                                      |                           |      |                 |
| DOX DOTAGA-OA        | 14.2ᵃ         | 5.1ᵃ                                 | 150 ± 12                  | 0.13 ± 0.03 | −17 ± 0.8       |
| 13.0ᵇ                 |                |                                      |                           |      |                 |

ᵃ25 °C. ᵇ37 °C.

**Figure 3.** cryo-TEM images of (A) blank cubosomes, (B) cubosomes loaded with DOX, (C) DOTAGA-OA, and (D) DOX and DOTAGA-OA.

**Table 4. Characterization of Cubosome Formulations Using SAXS and DLS**

**Figure 4.** (A) Cyclic voltammograms for DOX incorporated into mesophase with or without the DOTAGA-OA dopant. Scan rate: 100 mV/s, pH 5.5. (B) DPV recorded on GCE modified with DOX-containing cubic phases in 0.1 M MES buffer at pH 5.5. Amplitude: ΔE = 50 mV, pulse time: tᵣ = 50 ms.
and the PDI value was close to 0.18. For the DOTAGA-OA-doped cubosomes, the particle diameter was slightly lower (130 ± 15 nm) with a PDI value of approximately 0.12. For cubosomes loaded with DOX or DOX and DOTAGA-OA together, the diameter was close to 160 ± 10 nm with a PDI of 0.19 and 150 ± 12 with a PDI of 0.13, respectively. The obtained PDI values of cubosomes indicated homogeneity of the formulations and also demonstrated that the structures do not aggregate. The \( \zeta \) potentials obtained for the cubosomes were close to −29 mV for nondoped cubosomes and −24 mV for DOX-loaded nanoparticles. For cubosomes with DOTAGA-OA or DOX and DOTAGA-OA together, zeta potentials were −20 and −17 mV. These values implicated the stability of the obtained nanoparticles.

The cryo-TEM images obtained for blank and doped cubosomes showed the well-ordered internal structure of the nanoparticles (Figure 3). Cryo-TEM images showed that cubosomal dispersions also contain some fraction of vesicles in agreement with other reports.60,61

### 3.2. Release Studies of Doxorubicin in the Absence and Presence of DOTAGA-OA in the Cubic Phase Monitored by Electrochemical Methods

The electrochemical behavior of DOX incorporated in cubic phases was monitored using cyclic (CV) and differential pulse voltammetry (DPV) at pH 5.5, which corresponds to the tumor microenvironment. DOX is an electroactive molecule with one quinone (Q) and one hydroquinone (QH2) groups. The quinone or hydroquinone moieties undergo \( 2e^-/2H^+ \) reduction and oxidation processes, respectively (SI, Scheme 1S). The redox properties of adriamycines were described by Komorsky-Lovric,62 and the redox properties of DOX in cubic phases were described in more detail in our previous work.45

In the cubic phase, DOX undergoes reduction at approximately −0.5 V corresponding to the reduction of the 5,12-diquinone groups, while less reversible oxidation of the hydroquinone unit occurs at +0.74 V (Figure 4A). The reduction peak is used for determining the release kinetics of the drug from the cubic phase. Interestingly, when the cubic phase is doped with both DOX and DOTAGA-OA, the reduction peak of DOX is shifted toward more positive potential values. The change in the peak position indicates that the electron acceptor properties of the molecule become stronger either due to lower pH in the immediate environment of the reducing species (lower pH value due to the presence of the carboxylic moieties in the DOTAGA headgroup) or due to interactions between the DOX and DOTAGA-OA stronger for the reduced form of the drug.

This shift of reduction peak potentials is clearly seen in the voltammograms recorded by DPV (Figure 4B). Additionally, the height of the peak is decreasing, indicating that the diffusion of DOX to the electrode surface is slower when DOX is involved in the interactions with the macrocyclic ligand DOTAGA-OA. DOX at pH 5.5 is positively charged, while the DOTAGA-OA ligand is in its deprotonated form, which facilitates the interaction of the drug with the ligand. This effect will have to be taken into account in the simultaneous delivery of both drugs: chemo- and radiotherapeutic in the combined therapy.

The release study of DOX was carried out to determine how the presence of DOTAGA-OA ligand in the cubic phase influences the release profile of the incorporated chemo-therapeutic agent. The release profiles of DOX from mesophases were determined based on the changes of peak currents recorded by DPV with time following immersion of the electrodes into the buffer solution. With time, the peak currents decreased, reflecting the elution of the drug from the phase (Figures 5 and 1S (SI)). To quantify the release and to determine the release kinetics of the peak, current values were normalized to \( I/I_0 \), where \( I_0 \) is the DOX peak current at \( t_0 \) (Figure 5B).

Comparison of DOX release profiles reveals that the release of DOX in a measured time interval is retarded when the mesophase is doped with DOTAGA-OA. Similar effect was observed in the case of cubosomes (Figure 6). Release studies performed in a longer time interval −48 h of measurement confirmed that the release of DOX was slower in the presence of DOTAGA-OA ligand.

In the acidified medium (pH = 5.5) typical for cancer cell environment, the positively charged DOX is placed predominantly in the aqueous channels of the cubic phase, as

**Figure 5.** (A) Release profile of DOX-containing or DOX- and DOTAGA-OA-containing mesophases at pH 5.5. (B) The current normalized release profile of DOX from the mesophases plotted as a percentage of DOX released vs time.
previously described, and therefore, it diffuses fast from the cubic phase. However, interaction with DOTAGA-OA neutralizes its charge, which allows its penetration into the lipidic bilayers surrounding the water channels of the cubic phase. Diffusion from the lipidic part of the cubic phase is much slower. This explains why the presence of DOTAGA-OA ligand and its interaction with DOX delays the release of DOX from the cubic mesophase.

3.3. In Vitro Cytotoxicity Results of the MTS Assay. After the labeling of cubosomes with $^{213}$Bi (radiolabeling yield > 98%) and incorporation of chemotherapeutic, the obtained radioconjugates were tested in vitro. Cytotoxicity of cubosome dispersions containing DOTAGA-OA-complexed $^{213}$Bi and DOX, at three measurement points (24, 48, and 72 h) including three various doses (500, 1000, and 2000 kBq/mL) and a DOX concentration of 0.2 μg/mL (Figure 7A), was performed using the MTS assay. As preliminary MTS studies where DOX and $^{213}$Bi were incorporated simultaneously, cubosomes showed less toxicity (Figure 7B) of radioconjugate compared to cubosomes doped only with DOX due to the interactions of DOTAGA-OA ligand with DOX, as discussed above. The next experiments were performed using cubosomes containing the following components separately: complexed $^{213}$Bi ($^{213}$Bi-Cubo) and DOX-Cubo added to the cells sequentially.

The obtained viability results (Figure 7A) showed that the tested compounds caused a decrease in the metabolic activity of HeLa cells in a time- and dose-dependent manner. The addition of DOX-Cubo significantly reduces the viability of HeLa cells, and its impact on toxicity is dominant in comparison to toxicity deriving from radiation but only at lower doses (~500 and 1000 kBq/mL). The concentration of 0.2 μg/mL inhibits the metabolic activity of HeLa cells, and its effect is antagonistic to that of radiation.

Figure 6. Release profile of DOX-containing or DOX- and DOTAGA-OA-containing cubosomes measured by UV−vis spectroscopy.

Figure 7. (A) Viability of HeLa cells treated sequentially with $^{213}$Bi-Cubo/Cubo, Cubo/DOX-Cubo, and $^{213}$Bi-Cubo/DOX-Cubo after 24, 48, and 72 h of incubation, respectively. $^{213}$Bi-Cubo/Cubo and Cubo/DOX-Cubo were used as a control. (B) Viability of HeLa cells treated with $^{213}$Bi-Cubo, DOX-Cubo, and ($^{213}$Bi-Cubo + DOX)-Cubo after 24, 48, and 72 h of incubation, respectively. As a control, nontreated cells were used. Data points and SD are from at least three measurements. Statistical significance was considered if $p \leq 0.05$ (*), $p \leq 0.01$ (**), $p \leq 0.001$ (***) and $p \leq 0.0001$ (****).
μg/mL of DOX and 2000 kBq/mL of $^{213}$Bi loading cubosomes induce similar cytotoxicity in HeLa cells. In the case of $^{213}$Bi-Cubo/DOX-Cubo, the cytotoxicity effect is higher than for cubosomes doped only with $^{213}$Bi radionuclide or chemotherapy. The viability of HeLa cells exposed to $^{213}$Bi-Cubo and DOX-Cubo is the lowest (26%) with the use of 2000 kBq/mL of radioconjugate after 72 h of incubation. The results clearly demonstrated that the combined therapy with the highest dose of $^{213}$Bi and 0.2 μg/mL of DOX encapsulated

Figure 8. Graphs showing the percentage of apoptotic cells in vitro treated sequentially with $^{213}$Bi-Cubo/Cubo, Cubo/DOX-Cubo, and $^{213}$Bi-Cubo/DOX-Cubo at a DOX concentration of 0.2 μg/mL and 500 and 2000 kBq/mL of $^{213}$Bi radionuclide after 24 and 48 h of incubation. As a control, $^{213}$Bi-Cubo/Cubo and Cubo/DOX-Cubo were used. Data points and SD are from at least three measurements. Statistical significance was considered if $p \leq 0.05$ (*), $p \leq 0.01$ (**), $p \leq 0.001$ (***) and $p \leq 0.0001$ (****).

Figure 9. Cell cycle arrest in HeLa cells induced by $^{213}$Bi-Cubo/Cubo, Cubo/DOX-Cubo, and $^{213}$Bi-Cubo/DOX-Cubo. Percentages of cells in G0/G1, S, and G2/M phases ($n = 3 \pm SD$).
separately in cubosomes seems to be the best option for the treatment of cancer cells.

3.4. Apoptosis and Cell Cycle Studies. To determine whether the inhibition effect of DOX and α radiation incorporated in cubosomes is associated with triggering the programmed cell death pathways, apoptosis in human HeLa cancer cells was analyzed. The programmed cell death was evaluated by flow cytometry using Annexin V-FITC and PI fluorescence staining assay (Figure 2S).

The fraction of early apoptotic cells did not increase significantly upon the treatment with cubosomes doped with 213Bi and DOX compared to the control. Moreover, fewer early apoptotic cells were detected after 48 h than 24 h. Late apoptosis in HeLa cells appears to be more pronounced at higher doses, and an increase in induction is seen mostly in a time-dependent manner, which is in agreement with studies performed for another α emitter, 225Ac radionuclide. The highest apoptosis (57.7%) was observed in cells treated sequentially with 2000 kBq/mL 213Bi-Cubo/Cubo and 213Bi-Cubo/DOX-Cubo (500 kBq/mL of 213Bi; DOX concentration 0.2 μg/mL) and untreated (control) after 1, 3, and 10 days of incubation.

Figure 10. Bright-field (BF), propidium iodide (PI), and Hoechst 33258 (Hoechst) representative micrographs of HeLa spheroids treated with 213Bi-Cubo/Cubo, Cubo/DOX-Cubo, and 213Bi-Cubo/DOX-Cubo (500 kBq/mL of 213Bi; DOX concentration 0.2 μg/mL) and untreated (control) after 1, 3, and 10 days of incubation.

The fraction of early apoptotic cells did not increase significantly upon the treatment with cubosomes doped with 213Bi and DOX compared to the control. Moreover, fewer early apoptotic cells were detected after 48 h than 24 h. Late apoptosis in HeLa cells appears to be more pronounced at higher doses, and an increase in induction is seen mostly in a time-dependent manner, which is in agreement with studies performed for another α emitter, 225Ac radionuclide. The highest apoptosis (57.7%) was observed in cells treated sequentially with 2000 kBq/mL 213Bi-Cubo/DOX-Cubo after 48 h of incubation, whereas 213Bi-Cubo/Cubo and Cubo/DOX-Cubo induced lower apoptosis, 37.8 and 41.3%, respectively (Figure 8).

The combined 213Bi-Cubo/DOX-Cubo treatment resulted in the enhanced induction of apoptosis as compared to single treatments with either 213Bi-Cubo or DOX-Cubo. Overall, these findings indicate that the cell death of cubosomes encapsulated DOX and 213Bi occurs mainly through apoptosis.

To further characterize the effects of doped cubosomes on HeLa cells, the cell cycle was analyzed (Figure 3S). HeLa cell line was exposed to α-radiation with radioactivity levels of 500 and 2000 kBq/mL and to doxorubicin at a concentration of 0.2 μg/mL, separately incorporated in cubosomes. As shown in
DOX and negatively charged ligand complexing $^{213}$Bi. Sequential delivery of cubosomes, each with one drug, has been considered the best therapy for cancer cells.

In conclusion, a multimodal approach combining targeted radionuclide therapy with the administration of cytostatic drugs is a promising therapeutic concept that takes advantage of the synergistic effect of delivering both drugs encapsulated in separate carriers. Further studies should be directed toward the conjugation of the cubosomes with biomolecules targeting receptors overexpressed in tumor cells.

**ASSOCIATED CONTENT**

Supporting Information
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.2c00182.

Final compositions of the cubic phases doped with different amounts of DOTAGA-OA (Table 1S); phase parameter calculation based on SAXS measurements (1S); redox process of DOX (Scheme 1S); representative differential pulse voltammograms for DOX incorporated into mesophase with or without DOTAGA-OA dopant (Figure 1S); representative graphs of the flow cytometry analysis after the treatment of HeLa cells with $^{213}$Bi-Cubo/DOX-Cubo and with no treatment (Figure 2S); representative histograms of cell cycle analysis of HeLa cells after treatment with $^{213}$Bi-Cubo/DOX-Cubo and without the treatment (Figure 3S); and microscope representative images treated with $^{213}$Bi-Cubo/DOX-Cubo and untreated HeLa spheroids (Figure 4S) (PDF)

**AUTHOR INFORMATION**

Corresponding Author
Agnieszka Majkowska-Pilip – Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, 03-195 Warsaw, Poland; orcid.org/0000-0001-9449-6411; Email: a.majkowska@ichtj.waw.pl

Authors
Adrianna Cytryniak – Faculty of Chemistry, University of Warsaw, 02-093 Warsaw, Poland
Kinga Żelechowska-Matsiak – Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, 03-195 Warsaw, Poland
Ewa Nazaruk – Faculty of Chemistry, University of Warsaw, 02-093 Warsaw, Poland
Renata Bilewicz – Faculty of Chemistry, University of Warsaw, 02-093 Warsaw, Poland; orcid.org/0000-0003-0058-3691
Rafał Walczak – Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, 03-195 Warsaw, Poland
Emilia Majka – Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, 03-195 Warsaw, Poland
Adam Mames – Institute of Physical Chemistry, Polish Academy of Sciences, 01-224 Warsaw, Poland
Frank Bruchertseifer – Directorate for Nuclear Safety and Security, European Commission, Joint Research Centre, 76125 Karlsruhe, Germany
Alfred Morgenstern — Directorate for Nuclear Safety and Security, European Commission, Joint Research Centre, 76125 Karlsruhe, Germany
Aleksander Bilewicz — Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, 03-195 Warsaw, Poland

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.molpharmaceut.2c00182

Author Contributions
The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Funding
This work was supported by the National Science Center (Project No. 2017/25/B/ST4/02817). The contribution of Adrianna Cytryniak and Kinga Zalewska-Matysiak was realized within Project No. POW.03.02.00-00-1009/17-00 (Operational Project Knowledge Education Development 2014-2020 cofinanced by the European Social Fund). Agnieszka Majkowska-Pilip thanks the National Science Centre (Project No. 2018/31/D/ST4/01488) for financial support.

Notes
The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The cryo-EM imaging was conducted at the Cryomicroscopy and Electron Diffraction Core Facility, Center of New Technologies, University of Warsaw, Poland.

REFERENCES

(1) Schmitz, K. H.; Prosnitz, R. G.; Schwartz, A. L.; Carver, J. R. Prospective Surveillance and Management of Cardiac Toxicity and Health in Breast Cancer Survivors. Cancer 2012, 118, 2270–2276.
(2) McGowan, J. V.; Chung, R.; Maulik, A.; Piotrowska, I.; Walker, J. M.; Yellon, D. M. Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc. Drugs Ther. 2017, 31, 63–75.
(3) Baska, R.; Lee, K. A.; Yeo, R.; Yeoh, K. Cancer and Radiation Therapy: Current Advances and Future Directions. Int. J. Med. Sci. 2012, 9, 193–199.
(4) Iagaru, A.; Mittra, E. S.; Ganjoo, K.; Knox, S. J.; Goris, M. L.; Taskar, N.; Divgi, C. R.; Panageas, K. S.; Heaney, M. L.; Chanel, S.; Morgenstern, A.; Sgouros, G.; Larson, S. M.; Scheinberg, D. A.; Jurcic, J. G. Sequential Cytarabine and Anthracycline Chemotherapy for Acute Myeloid Leukemia. Clin. Cancer Res. 2010, 16, 5303–5311.
(5) Kunikowska, J.; Królicki, L.; Hubalewska-Dydejczyk, A.; Mikolajczak, R.; Sowa-Statzczak, A.; Pawlak, D. Clinical Results of Radionuclide Therapy of Neuroendocrine Tumours Using 90Y-DOTATATE and Tandem 90Y/177Lu-DOTATATE: Which Is a Better Therapy Option? Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 1788–1797.
(6) Yu, Z.; Ananias, H. J. K.; Carlucci, G.; Hoving, H. D.; Helfrich, W.; Dierckx, R. A. J. O.; Wang, F.; Jong, I. J. de.; Elinga, P. H. An Update of Radiolabeled Bombsin Analogs for Gastrin-Releasing Peptide Receptor Targeting. Curr. Pharm. Des. 2013, 19, 3329–3341.
(7) Zoller, F.; Eisenhut, M.; Haberkorn, U.; Mier, W. Endo- raditherapy in Cancer Treatment — Basic Concepts and Future Trends. Eur. J. Pharmaco. 2009, 625, 55–62.
(8) Satheke, M.; Bruchterseifer, F.; Knoesen, O.; Reyneke, F.; Lawal, I.; Lengana, T.; Davis, C.; Mahapane, J.; Corbett, C.; Vorster, M.; Morgenstern, A. 225Ac-PSMA-617 in Chemotherapy-Naive Patients with Advanced Prostate Cancer: A Pilot Study. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 129–138.
(9) Clemens, K.; Frank, B.; Hendrik, R.; Hohenfellner, M.; Frederik, L.; Uwe, H.; Alfred, M. Targeted Alpha-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control. J. Nucl. Med. 2018, 59, 795–802.
(10) Dekempeneer, Y.; Caveliers, V.; Ooms, M.; Maertens, D.; Gysemans, M.; Lahoutte, T.; Xavier, C.; Lecoq, Q.; Maes, K.; Covens, P.; Miller, B. W.; Bruchterseifer, F.; Morgenstern, A.; Cardinaels, T.; Huyvetter, M. D. Therapeutic Efficacy of 213Bi-Labeled SdAbs in a Preclinical Model of Ovarian Cancer. Mol. Pharm. 2020, 17, 3553–3566.
(11) Zalutsky, M. R. Radionuclide Therapy. In Handbook of Nuclear Chemistry Volume 4: Radiochemistry and Radiopharmaceutical Chemistry in Life Sciences; Roesch, F., Ed.; Kluwer Academic Publishers: Dordrecht, 2003; pp 315–348.
(12) Zalutsky, M. R.; Reardon, D. A.; Pozzi, O. R.; Vaidyanathan, G.; Bigner, D. D. Targeted Alpha-Particle Radiotherapy with 211At-Labeled Monoclonal Antibodies. Nucl. Med. Biol. 2007, 34, 779–785.
(13) Majkowska-Pilip, A.; Gwęda, W.; Zalewska-Matysiak, K.; Wawrowicz, K.; Bilewicz, A. Nanoparticles in Targeted Alpha Therapy. Nanomaterials 2020, 10, No. 1366.
(14) Marouli, M.; Van; Jobba, V.; Stroh, H.; et al. Decay Data Measurements on 213Bi Using Recoil Atoms. Appl. Radiat. Isot. 2013, 74, 123–127.
(15) Morgenstern, A.; Apostolidis, C.; Kratochwil, C.; Satheke, M.; Krölicki, L.; Bruchterseifer, F. An Overview of Targeted Alpha Therapy with 225 Actinium and 213 Bismuth. Curr. Radiopharm. 2018, 11, 200–208.
(16) Krölicki, L.; Bruchterseifer, F.; Kunikowska, J.; Koziara, H.; Krölicki, B.; Jakuciński, M.; Jakuci, M.; Pawlak, D.; Apostolidis, C.; Mirzadeh, S.; Rola, R.; Merlo, A. Safety and Efficacy of Targeted Alpha Therapy with 213 Bi-DOTAPhosphate Substance P in Recurrent Glioblastoma. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 614–622.
(17) Krölicki, L.; Bruchterseifer, F.; Kunikowska, J.; Koziara, H.; Krölicki, B.; Jakuciński, M.; Pawlak, D.; Apostolidis, C.; Mirzadeh, S.; Rola, R.; Merlo, A.; Morgenstern, A. Prolonged Survival in Secondary Glioblastoma Following Local Injection of Targeted Alpha Therapy with 213Bi-Substance P Analogue. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 1636–1644.
(18) Kratochwil, C.; Giesel, F. L.; Bruchterseifer, F.; Mier, W. Bi-DOTATOC Receptor-Targeted Alpha-Radionuclide Therapy Induces Remission in Neuroendocrine Tumours Refractory to Beta Radiation: A First-in-Human Experience. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 2106–2119.
(19) Rosenblat, T. L.; McDevitt, M. R.; Mulford, D. A.; Pandit-Taskar, N.; Divgi, C. R.; Panageas, K. S.; Heaney, M. L.; Chanel, S.; Morgenstern, A.; Gouros, G.; Larson, S. M.; Scheinberg, D. A.; Jurcic, J. G. Sequential Cyttarine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia. Clin. Cancer Res. 2010, 16, S303–S311.
(20) Juric, J. G.; Larson, S. M.; Gouros, G.; Mcdevitt, M. R.; Finn, R. D.; Divgi, C. R.; Ballangrud, ÅM.; Hamacher, K. A.; Ma, D.; Humm, J. L.; Brechbiel, M. W.; Molenet, R.; Scheinberg, D. A. Targeted Alpha Particle Immunotherapy for Myeloid Leukemia. Blood 2002, 100, 1233–1239.
(21) Allen, B. J.; Raja, C.; Rizvi, S.; Li, Y.; Tsui, W.; Graham, P.; Thompson, J.; Reisfeld, R.; Kearsley, J.; Morgenstern, A.; Allen, B. J.; Raja, C.; Rizvi, S.; Li, Y.; Tsui, W.; Graham, P.; Thompson, J.; Reisfeld, R.; Kearsley, J.; Morgenstern, A.; Apostolidis, C.; Allen, B. J.; Raja, C.; Rizvi, S.; Li, Y.; Tsui, W.; Graham, P.; Thompson, J.; Reisfeld, R. A.; Kearsley, J.; Morgenstern, A.; Apostolidis, C. Intratargeted Alpha-Therapy of Metastatic Melanoma. Cancer Biol. Ther. 2005, 4, 1318–1324.
(22) Raja, C.; Graham, P.; Rizvi, S.; Song, E.; Goldsmith, H.; Thompson, J.; Bosserhoff, A.; Morgenstern, A.; Apostolidis, C.; Kearsley, J.; Reisfeld, R.; Allen, B. J. Interim Analysis of Toxicity and Response in Phase 1 Trial of Systemic Targeted Alpha Therapy for Metastatic Melanoma. Cancer Biol. Ther. 2007, 6, 846–852.
(23) Allen, B. J.; Singla, A. A.; Rizvi, S. M. A.; Graham, P.; Bruchterseifer, F.; Apostolidis, C.; Morgenstern, A. Analysis of Patient
Survival in a Phase I Trial of Systemic Targeted \(\alpha\)-Therapy for Metastatic Melanoma. *Immunotherapy* 2011, 3, 1041–1050.

(24) Autenrieth, M. E.; Seidl, C.; Bruchterseifer, F.; Horn, T.; Kurtz, F.; Feuerrecker, B.; D’Alessandria, C.; Pfob, C.; Nekolla, S.; Apostolidis, C.; Mirzadeh, S.; Gschwand, J. E.; Schwager, M.; Scheidhauer, K.; Morgenstern, A. Treatment of Carcina in Situ of the Urinary Bladder with an Alpha-Emitter Immunocugnome Targeting the Epidermal Growth Factor Receptor: A Pilot Study. *Eur. J. Nucl. Med. Mol. Imaging* 2018, 45, 1364–1371.

(25) Senapati, S.; Mahanta, A. K.; Kumar, S.; Maiti, P. Controlled Drug Delivery Vehicles for Cancer Treatment and Their Performance. *Signal Transduction Targeted Ther.* 2018, 3, No. 7.

(26) Sofou, S.; Thomas, J. L.; Lin, H.; McDevitt, M. R.; Scheinberg, D. A.; Sgouros, G. Engineered Liposomes for Potential \(\alpha\)-Particle Therapy of Metastatic Cancer. *J. Nucl. Med.* 2004, 45, 253–253260.

(27) Chang, M.-Y.; Seideman, J.; Sofou, S. Enhanced Loading Efficiency and Retention of 225Ac in Rigid Liposomes for Potential Targeted Therapy of Micrometastases. *Bioconjugate Chem.* 2008, 19, 1274–1282.

(28) Zhu, C.; Sempkowski, M.; Holleran, T.; Linz, T.; Bertalan, T.; Josefsson, A.; Bruchterseifer, F.; Morgenstern, A.; Sofou, S. Alpha-Particle Radiotherapy: For Large Solid Tumors Diffusion Trumps Efficiency and Retention of 225Ac in Rigid Liposomes for Potential Targeted Therapy of Micrometastases. *Bioconjugate Chem.* 2008, 19, 1274–1282.

(29) Sofou, S.; Kappel, B. J.; Jaggi, J. S.; McDevitt, M. R.; Scheinberg, D. A.; Sgouros, G. Enhanced Retention of the \(\alpha\)-Particle-Emitting Daughters of Actinium-225 by Liposome Carriers. *Bioconjugate Chem.* 2007, 18, 2061–2067.

(30) Henricksen, G.; Scholtz, B. W.; Michaeli, T. E.; Bruoland, OS; Larsen, R. H. Sterically Stabilized Liposomes as a Carrier for \(\alpha\)-Emitting Radium and Actinium Radionuclides. *Nucl. Med. Biol.* 2004, 31, 441–449.

(31) Lingappa, M.; Song, H.; Thompson, S.; Bruchterseifer, F. Immunoposilosomal Delivery of \(\alpha\)-Metastatic Breast Cancer Bi for \(\alpha\)-Emitting Targeted Cancer. *Cancer Res.* 2010, 70, 6815–6824.

(32) Jonasdottir, T. J.; Fisher, D. R.; Borrebaek, J.; Bruland, Ø. S.; Larsen, R. H. First In Vivo Evaluation of Liposome-Encapsulated 223 Ra as a Potential Alpha-Particle-Emitting Cancer Therapeutic Agent. *Anticancer Res.* 2006, 26, 2841–2848.

(33) Guo, C.; Wang, J.; Cao, F.; Lee, R. J.; Zhai, G. Lyotropic Liquid Crystal Systems in Drug Delivery. *Drug Discovery Today* 2010, 15, 1032–1040.

(34) Hinton, T. M.; Grusche, F.; Acharya, D.; Shukla, R.; Bansal, V.; Waddington, L. J.; Monaghan, P.; Muir, B. W. Bicontinuous Cubic Phase Nanoparticle Lipid Chemistry Affects Toxicity in Cultured Crystal Systems in Drug Delivery. *J. Colloid Interface Sci.* 2020, 2061, 2067.

(35) Sofou, S.; R.; Favereau, L.; Crassous, J.; Cytryniak, A.; Bilewicz, R.; Hrbáč, J.; Storch, J.; Žádný, J.; Vacek, J. Flavin-Helincene Amphiphilic Hybrids: Synthesis, Characterization, and Preparation of Surface-Supported Films. *Chemphyschem* 2021, 86, 982–990.

(36) Duly, M.; Brasnott, C.; Djechhader, A.; Seddon, A.; Nealan, J.; Murray, D.; Butler, J.; Soulisme, T.; Hudson, S. P. Modulating the Release of Pharmaceuticals from Lipid Cubic Phases Using a Lipase Inhibitor.* Colloids Interface Sci.* 2020, 573, 176–192.

(37) Nazaruk, E.; Majewska-Pilip, A.; Bilewicz, R. Cubic Lipid Phase Nanoparticles-Cubosomes for Efficient Drug Delivery to Cancer Cells. *Chemphyschem* 2017, 82, 570–575.

(38) Mierzwa, M.; Cytryniak, A.; Kryński, P.; Bilewicz, R. Lipidic Liquid Cubic Phase Cubes and Magnetocubosomes as Methotrexate Carriers. *Nanomaterials* 2019, 9, 636.

(39) Gajda, E.; Godlewksa, M.; Mariak, Z.; Nazaruk, E.; Gawel, D. Combimatory Treatment with Mir-7-Sp and Drug-Loaded Cubosomes Effectively Impairs Cancer Cells. *Int. J. Mol. Sci.* 2020, 21, No. 5039.

(40) Aleandri, S.; Bandera, D.; Mezzenga, R.; Landau, E. M. Biotinylated Cubosomes: A Versatile Tool for Active Targeting and Codelivery of Paclitaxel and a Fluorescein-Based Lipid Dye. *Langmuir* 2015, 31, 12770–12776.

(41) Zhang, L.; Li, J.; Tian, D.; Sun, L.; Wang, X.; Tian, M. Theranostic Combinatorial Drug-Loaded Coated Cubosomes for Enhanced Targeting and Efficacy against Cancer Cells. *Cell Death Dis.* 2020, 11, 1.

(42) Li, Y.; Angelova, A.; Hu, F.; Garamus, V. M.; Peng, C.; Li, N.; Liu, J.; Liu, D.; Zou, A. PH Responsiveness of Hexosomes and Cubosomes for Combined Delivery of Brucea Javanica Oil and Doxorubicin. *Langmuir* 2019, 35, 14532–14542.

(43) Cytryniak, A.; Nazaruk, E.; Bilewicz, R.; Góźyńska, E.; Zelechowska-Matyasiak, K.; Walczak, R.; Mmes, A.; Bilewicz, A.; Majewska-Pilip, A. Lipidic Cubic-Phase Nanoparticles (Cubosomes) Loaded with Doxorubicin and Labeled With177 Lu as a Potential Tool for Combined Chemotherapy and Internal Radiotherapy for Cancers. *Nanomaterials* 2020, 10, No. 2272.

(44) Morgenstern, A.; Bruchterseifer, F.; Apostolidis, C. Bismuth-213 and Actinium-225 – Potential Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes. *Curr. Radiopharm.* 2012, 5, 221–227.

(45) Qiu, H.; Caffrey, M. The Phase Diagram of the Monoolein/Water System: Metastability and Equilibrium Aspects. *Biomaterials* 2000, 21, 233–234.

(46) Nakano, M.; Sugita, A.; Matsuoka, H.; Handa, T. Small-Angle X-Ray Scattering and 13C NMR Investigation on the Internal Structure of Cubosomes. *Langmuir* 2001, 17, 3917–3922.

(47) Chong, J. Y. T.; Mulet, X.; Waddington, L. J.; Boyd, B. J.; Drummond, C. J. Steric Stabilisation of Self-Assembled Cubic Lyotropic Liquid Cubic Nanoparticles: High Throughput Evaluation of Triblock Polyethylene Oxide-Polypropylene Oxide-Polyethylene Oxide Copolymers. *Soft Matter* 2011, 7, 4768–4777.
(60) Demurtas, D.; Guichard, P.; Martiel, I.; Mezzenga, R.; Hébert, C.; Sagalowicz, L. Direct Visualization of Dispersed Lipid Bicontinuous Cubic Phases by Cryo-Electron Tomography. *Nat. Commun.* **2015**, *6*, No. 8915.

(61) Gustafsson, J.; Ljusberg-Wahren, H.; Almgren, M.; Larsson, K. Submicron Particles of Reversed Lipid Phases in Water Stabilized by a Nonionic Amphiphilic Polymer. *Langmuir* **1997**, *13*, 6964–6971.

(62) Komorsky-Lovrić, S. Redox Kinetics of Adriamycin Adsorbed on the Surface of Graphite and Mercury Electrodes. *Bioelectrochemistry* **2006**, *69*, 82–87.

(63) Nazaruk, E.; Miszta, P.; Filipesk, S.; Górecka, E.; Landau, E. M.; Bilewicz, R. Lyotropic Cubic Phases for Drug Delivery: Diffusion and Sustained Release from the Mesophase Evaluated by Electrochemical Methods. *Langmuir* **2015**, *31*, 12753–12761.

(64) Fournier, C.; Taucher-Scholz, G. Radiation Induced Cell Cycle Arrest: An Overview of Specific Effects Following High-LET Exposure. *Radiother. Oncol.* **2004**, *73*, S119–S122.

(65) Graf, F.; Fahrer, J.; Maus, S.; Morgenstern, A.; Bruchertseifer, F.; Venkatachalam, S.; Fottner, C.; Weber, M. M.; Huelsenbeck, J.; Schreckenberger, M.; Kaina, B.; Miederer, M. DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy. *PLoS One* **2014**, *9*, e88239–e88239.

(66) Vallon, M.; Seidl, C.; Blechert, B.; Li, Z.; Gilbertz, K.-P.; Baumgart, A.; Aichler, M.; Feuchtinger, A.; Gaertner, F. C.; Bruchertseifer, F.; Morgenstern, A.; Walch, A. K.; Senekowitsch-Schmidtk, R.; Essler, M. Enhanced Efficacy of Combined 213Bi-DTPA-F3 and Paclitaxel Therapy of Peritoneal Carcinomatosis Is Mediated by Enhanced Induction of Apoptosis and G2/M Phase Arrest. *Eur. J. Nucl. Med. Mol. Imaging* **2012**, *39*, 1886–1897.

(67) Kim, H.-S.; Lee, Y.-S.; Kim, D.-K. Doxorubicin Exerts Cytotoxic Effects through Cell Cycle Arrest and Fas-Mediated Cell Death. *Pharmacology* **2009**, *84*, 300–309.